title: Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.
abstract: Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.
authors.affiliation: Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, P.le S.M. della Misericordia, 15, 33100, Udine, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Vescini
authors.affiliation: Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy. roberto.serena@libero.it.
authors.forename: R
authors.initials: R
authors.lastname: Attanasio
authors.affiliation: Unit of Endocrinology and Diabetology, Department of Internal Medicine, M. Bufalini Hospital, Cesena, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Balestrieri
authors.affiliation: Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Brazil.
authors.forename: F
authors.initials: F
authors.lastname: Bandeira
authors.affiliation: Istituto Auxologico Italiano, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bonadonna
authors.affiliation: Unit of Endocrinology, Department of Medicine, University of Padova, Padua, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Camozzi
authors.affiliation: Endocrinology and Diabetology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Cassibba
authors.affiliation: Endocrinology, S. Maria Goretti Hospital, Latina, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Cesareo
authors.affiliation: Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Chiodini
authors.affiliation: Post Acute and Long Term Care Department, I.N.R.C.A., Ancona, Italy.|San Pier Damiano Hospital, Villa Maria Group Care and Research, Faenza, Ravenna, Italy.
authors.forename: C Maria
authors.initials: CM
authors.lastname: Francucci
authors.affiliation: Endocrinology and Metabolic Diseases, S. Croce e Carle Hospital, Cuneo, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Gianotti
authors.affiliation: Endocrinology and Metabolic Disease Unit, Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, P.le S.M. della Misericordia, 15, 33100, Udine, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Grimaldi
authors.affiliation: Endocrinology Unit, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Guglielmi
authors.affiliation: Integrated Department of Medicine, Endocrinology and Metabolism, Geriatrics, University of Modena and Reggio Emilia, Modena, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Madeo
authors.affiliation: Endocrine Unit 2, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Marcocci
authors.affiliation: Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Palermo
authors.affiliation: Endocrinology, Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Scillitani
authors.affiliation: Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Vignali
authors.affiliation: Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Rochira
authors.affiliation: Endocrinology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Zini
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D032921:Consensus; D000072097:Endocrinologists; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control*
chemical_list: D050071:Bone Density Conservation Agents
keywords: Adherence; Androgen deprivation; Aromatase inhibitors; Bisphosphonates; Denosumab; Drug-induced osteoporosis; Fracture; Length of therapy; Male osteoporosis; Non-responder; Osteoporosis; SERMs; Side effects; Strontium ranelate; Teriparatide; Treatment